|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
Novo Nordisk expects its sales to decline, on an adjusted basis, by between 5% and 13% this year.
Pricing pressures and increased competition are weighing on its growth prospects.
The company recently obtained approval for its weight loss pill.
The share price of Novo Nordisk (NYSE: NVO) plunged by nearly 15% on Tuesday after the company posted sales and earnings numbers for its most recent quarter and released its 2026 guidance, which was downright awful.
Investors have been selling the stock in droves. Is it doomed and heading lower, or could this be a good time to buy the stock at a massive discount?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
The big news that shook the stock market was the Denmark-based pharmaceutical giant's outlook for the year. Due to pricing pressure and rising competition in the GLP-1 market, the healthcare company is projecting its adjusted sales to drop between 5% and 13% this year. These are adjusted numbers that effectively represent what the company expects its true organic rate to be for the year.
It's a huge disappointment for the GLP-1 drug maker, especially after it recently obtained approval for its GLP-1 weight loss pill. The stock was doing well up until this recent news shattered investor confidence.
However, if demand for its weight loss pill proves to be stronger than anticipated, there could be upgrades to the guidance over time. Plus, with the stock trading at just 14 times its trailing earnings, it's a decent value buy at its current levels. The average stock on the S&P 500 trades at nearly 26 times its earnings.
As bad as things may seem, Novo Nordisk still has a robust diabetes and obesity business that should grow over the years. With it still in the early stages of rolling out its weight loss pill, it can still be a good buy for the long haul. Investors shouldn't panic on this news, as it may prove to be a great buying opportunity.
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $431,111!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,521!*
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 4, 2026.
David Jagielski, CPA has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
| 28 min |
Eli Lilly Surges On 'Assertive' Guidance That Assuages Novo Nordisk-Tied Worries
NVO -6.18%
Investor's Business Daily
|
| 29 min |
Novo Continues Two-Day Plunge As CFO Acknowledges 'Extraordinary' Challenges In 2026
NVO -6.18%
Investor's Business Daily
|
| 36 min | |
| 48 min | |
| 1 hour | |
| 1 hour | |
| 2 hours | |
| 2 hours | |
| 2 hours | |
| 2 hours | |
| 4 hours | |
| 4 hours | |
| 4 hours | |
| 4 hours | |
| 4 hours |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite